الجمعة 12 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| Intra Peritoneal Instillation of Ropivacaine with or without Dexmedetomidine for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy. A randomized controlled | King Abdullah Medical City, Makkah | Completed | Dexmedetomidine | 2 | version 4 | King Abdullah Medical City (Makkah) |
| Vitamin D Status Correction and Validation of its Potential Clinical Utility through Discovery Proteomic Analysis | Prince Mutaib Chair for Biomarkers of Osteoporosis/synergypha-rma | Completed | cholecalciferol | 3 | E-15-1667 | King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) | AstraZeneca | Completed | Osimertinib (AZD9291) | 3 | D5160C00022 | King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | AstraZeneca | Terminated | Osimertinib (AZD9291) | 3 | D5160C00007 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study | McMaster University | Terminated | haemagglutinin (HA)/Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) | 3 | Version date Sep-3-2013 | King Khalid University Hospital (Riyadh) |
| Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study. | Onxeo | Completed | Doxorubicin | 3 | BA2011/03/04 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
| Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations | PSCDR | Completed | rAAV2-VMD2-hMERTK | 1 | rAAV2-VMD2-hMERTK | King Faisal Specialist Hospital and Research Center (Riyadh), King Khaled Eye Specialist Hospital (Riyadh) |
| A Compartive Multicenter Study of Neoadjuvant Docetaxel/Cisplatin Followed by Concurrent Cisplatin with Radiotherapy using Intensity-Modulated Radition Therapy (IMRT) with or without Bevacizumab for Locally Advanced Nasopharyngeal Cancer | King Fahad Medical City | Terminated | Docetaxel/Cisplatin and Bevacizumab | 3 | Version 1.3 date 6 may 2012 | King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| "An open-label extension study of the long-term safety,tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)." | GSK | Terminated | Ambrisentan | 3 | 116457 | King Fahad Medical City (Riyadh) |
| Efficacy of lntra-cervical Misoprostol in the Management of Early Pregnancy Failure: Randumized Clinical Trial | King Abdulaziz University Hospital | Rejected | Misoprostol | 2 | 227-15 | King Abdulaziz University Hospital (Jeddah) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.